Iron, haemochromatosis and thalassaemia as risk factors for fibrosis in hepatitis C virus infection

Gut

Volumn 56, Issue 5, 2007, Pages 613-614

  Thursz, Mark ^a  

^a Gastroenterology and Hepatology Research   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERIPRONE; HFE PROTEIN; IRON;

GENE MUTATION; HEMOCHROMATOSIS; HEPATITIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IRON CHELATION; IRON DEPLETION; IRON OVERLOAD; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER INJURY; NONHUMAN; NOTE; PRIORITY JOURNAL; RISK FACTOR; THALASSEMIA;

HEMOCHROMATOSIS; HEPATITIS C, CHRONIC; HUMANS; IRON OVERLOAD; LIVER CIRRHOSIS; RISK FACTORS; THALASSEMIA;

EID: 34247547346     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2006.113076     Document Type: Note

References (36)

1. Bacon BR, Tavill AS, Brittenham GM, et al. Hepatic lipid peroxidation in vivo in rats with chronic iron overload. J Clin Invest 1983;71:429-39.
2. Galli A, Svegliati-Baroni G, Ceni E, et al. Oxidative stress stimulates proliferation and invasiveness of hepatic stellate cells via a MMP2-mediated mechanism. Hepatology 2005;41:1074-84.
3. Tavill AS, Qadri AM. Alcohol and iron. Semin Liver Dis 2004;24:317-25.
4. Bonkovsky HL, Troy N, McNeal K, et al. Iron and HFE or TfR1 mutations as comorbid factors for development and progression of chronic hepatitis C. J Hepatol 2002;37:848-54.
5. Fernandez-Rodriguez CM, Gutierrez ML, Serrano PL, et al. Factors influencing the rate of fibrosis progression in chronic hepatitis C. Dig Dis Sci 2004;49:1971-6.
6. Lin TJ, Liao LY, Lin SY, et al. Influence of iron on the severity of hepatic fibrosis in patients with chronic hepatitis C. World J Gastroenterol 2006;12:4897-901.
7. Rigamonti C, Andorno S, Maduli E, et al. Iron, hepatic stellate cells and fibrosis in chronic hepatitis C. Eur J Clin Invest 2002;32(Suppl 1):28-35.
8. Thorburn D, Curry G, Spooner R, et al. The role of iron and hemochromatosis gene mutations in the progression of liver disease in chronic hepatitis C. Gut 2002;50:248-52.
9. Wright M, Goldin R, Fabre A, et al. Measurement and determinants of the natural history of liver fibrosis in hepatitis C virus infection: a cross sectional and longitudinal study. Gut 2003;52:574-9.
10. Poynard T, Bedossa P, Opoton P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-32.
11. Ryder SD, Irving WL, Jones DA, et al. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut 2004;53:451-5.
12. Hillebrandt S, Wasmuth HE, Weiskirchen R, et al. Complement factor 5 is a quantitative trait gene that modifies liver fibrogenesis in mice and humans. Nat Genet 2005;37:835-43.
13. Wright M, Goldin R, Hellier S, et al. Factor V Leiden polymorphism and the rate of fibrosis development in chronic hepatitis C virus infection. Gut 2003;52:1206-10.
14. Huang H, Shiffman ML, Cheung RC, et al. Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C. Gastroenterology 2006;130:1679-87.
15. Smith BC, Gorve J, Guzail MA, et al. Heterozygosity for hereditary hemochromatis is associated with more fibrosis in chronic hepatitis C. Hepatology 1998;27:1695-9.
16. Martinelli AL, Franco RF, Villanova MG, et al. Are haemochromatosis mutations related to the severity of liver disease in hepatitis C virus infection? Acta Haematol 2000;102:152-6.
17. Tung BY, Emond MJ, Bronner MP, et al. Hepatitis C, iron status, and disease severity: relationship with HFE mutations. Gastroenterology 2003;124:318-26.
18. Hohler T, Leininger S, Kohler HH, et al. Heterozygosity for the hemochromatosis gene in liver diseases-prevalence and effects on liver histology. Liver 2000;20:482-6.
19. Sartori M, Andorno S, Pagliarulo M, et al. Heterozygous B globin gene mutations as a risk factor for iron accumulation and liver fibrosis in chronic hepatitis C. Gut 2007;56:693-8.
20. Beutler E, Felitti VJ, Koziol JA, et al. Penetrance of 845G-> A (C282Y) HFE hereditary haemochromatosis mutation in the USA. Lancet 2002;359:211-18.
21. Waalen J, Felitti V, Gelbart T, et al. Prevalence of hemochromatosis-related symptoms among individuals with mutations in the HFE gene. Mayo Clin Proc 2002;77:522-30.
22. Waalen J, Felitti V, Gelbart T, et al. Penetrance of hemochromatosis. Blood Cells Mol Dis 2002;29:418-32.
23. Bulaj ZJ, Ajioka RS, Phillips JD, et al. Disease-related conditions in relatives of patients with hemochromatosis. N Engl J Med 2000;343:1529-35.
24. Olynyk JK, Cullen DJ, Aquilia S, et al. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 1999;341:718-24.
25. Kattarnis A, Papassotiriou I, Palaiologou D, et al. The effects of erythropoetic activity and iron burden on hepcidin expression in patients with thalassemia major. Haematologica 2006;91:809-12.
26. Angelucci E, Muretto P, Nicolucci A, et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood 2002;100:17-21.
27. Vento S, Cainelli F, Cesario F. Infections and thalassaemia. Lancet Infect Dis 2006;6:226-33.
28. Theurl I, Zoller H, Obrist P, et al. Iron regulates hepatitis C virus translation via stimulation of expression of translation initiation factor 3. J Infect Dis 2004;190:819-25.
29. Kakizaki S, Takagi H, Horiguchi N, et al. Iron enhances hepatitis C virus replication in cultured human hepatocytes. Liver 2000;20:125-8.
30. Choi J, Ou JH. Mechanisms of liver injury. III. Oxidative stress in the pathogenesis of hepatitis C virus. Am J Physiol Gastrointest Liver Physiol 2006;290:G847-51.
31. Moriya K, Nakagawa K, Santa T, et al. Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. Cancer Res 2001;61:4365-70.
32. Furutani T, Hino K, Okuda M, et al. Hepatic iron overload induces hepatocellular carcinoma in transgenic mice expressing the hepatitis C virus potyprotein. Gastroenterology 2006;130:2087-98.
33. Di Bisceglie AM, Bonkovsky HL, Chopra S, et al. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial. Hepatology 2000;32:135-8.
34. Iwasa M, Kaito M, Ikoma J, et al. Dietary iron restriction improves aminotransferase levels in chronic hepatitis C patients. Hepatogastroenterology 2002;49:529-31.
35. Wanless IR, Sweeney G, Dhillon AP, et al. Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood 2002;100:1566-9.
36. Wu SF, Peng CT, Wu KH, et al. Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients. Hemoglobin 2006;30:215-18.